CG Oncology's (CGON) Overweight Rating Reiterated at Cantor Fitzgerald

CG Oncology (NASDAQ:CGON - Get Free Report)'s stock had its "overweight" rating reaffirmed by Cantor Fitzgerald in a note issued to investors on Monday,Benzinga reports. They presently have a $75.00 price target on the stock. Cantor Fitzgerald's price objective would indicate a potential upside of 147.21% from the stock's current price.

CGON has been the subject of a number of other reports. Scotiabank initiated coverage on shares of CG Oncology in a report on Wednesday, April 16th. They set a "sector perform" rating and a $23.00 price objective for the company. Morgan Stanley reiterated an "overweight" rating and issued a $55.00 price objective on shares of CG Oncology in a report on Friday, March 7th. TD Cowen assumed coverage on shares of CG Oncology in a report on Tuesday, January 7th. They set a "buy" rating for the company. Finally, HC Wainwright restated a "buy" rating and issued a $75.00 price objective on shares of CG Oncology in a research report on Monday. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, CG Oncology presently has an average rating of "Buy" and an average target price of $59.33.

CG Oncology Stock Performance

Shares of NASDAQ CGON traded up $7.97 during trading hours on Monday, hitting $30.34. The stock had a trading volume of 4,432,990 shares, compared to its average volume of 888,896. The company has a market capitalization of $2.31 billion, a P/E ratio of -21.51 and a beta of 1.24. The firm's 50-day moving average price is $23.61 and its two-hundred day moving average price is $29.22. CG Oncology has a 52 week low of $14.80 and a 52 week high of $46.99.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.11). CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.11 million. As a group, analysts expect that CG Oncology will post -1.31 EPS for the current fiscal year.

Institutional Investors Weigh In On CG Oncology

A number of institutional investors have recently added to or reduced their stakes in CGON. NEOS Investment Management LLC lifted its position in shares of CG Oncology by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 8,329 shares of the company's stock worth $239,000 after acquiring an additional 817 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in CG Oncology by 3.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,080 shares of the company's stock valued at $862,000 after buying an additional 1,026 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of CG Oncology during the fourth quarter valued at about $41,000. Rhumbline Advisers lifted its holdings in shares of CG Oncology by 2.2% in the fourth quarter. Rhumbline Advisers now owns 69,016 shares of the company's stock worth $1,979,000 after buying an additional 1,458 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of CG Oncology by 16.4% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,834 shares of the company's stock valued at $368,000 after acquiring an additional 1,810 shares during the period. 26.56% of the stock is owned by institutional investors.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.